Search Results 751-760 of 18383 for alopecia

1. Study to Evaluate the Safety, Tolerability and Antitumor Activity of Anti-B7-H3 Car-T Cell Injection (TX103) in Subjects With Recurrent or Progressive Grade 4 Glioma - Mayo Clinic

   The toxicity and side effects caused by previous treatment have not recovered to ≤ grade 1 (per CTCAE 5.0); except for alopecia and other tolerable events ...

2. When someones weight loss journey hasnt gone as planned

   Simon Laplante, M.D., Metabolic Surgeon, Mayo Clinic: Obesity is a very chronic condition. It's a very complex condition that affects multiple systems in ...

3. A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma - Mayo Clinic

   Patients with Grade 2 neuropathy or Grade 2 alopecia are eligible. Active idiopathic thrombocytopenic purpura. Active central nervous system (CNS) ...

4. A Study of SAR442085 in Relapsed or Refractory Multiple Myeloma - Mayo Clinic

   ... alopecia). Participant has congestive heart failure (New York Heart Association) Grade ≥ II; cardiac myopathy, active ischemia, or any other uncontrolled ...

5. A Study to Evaluate the Safety and Therapeutic Activity of GI-102 in Patients With Advanced Solid Tumors - Mayo Clinic

   ... alopecia and Grade 2 peripheral neuropathy. HIV infected patients must be on anti-retroviral therapy (ART) and have a well-controlled HIV infection/disease ...

6. MDM2 Inhibitor AMG-232 and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma - Mayo Clinic

   ... alopecia (Grade 2 or 3 toxicities from prior antitumor therapy that are considered irreversible [defined as having been present and stable for > 6 months] ...

7. A Study to Assess the Effectiveness of Osimertinib Plus Savolitinib in Patients with Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Progressed Following Osimertinib Treatment (SAVANNAH Study) Following Prior Osimertinib - Mayo Clinic

   ... alopecia and Grade 2, prior platinum-therapy related neuropathy. As judged by the investigator, active gastrointestinal disease or other condition that will ...

8. A Study to Assess the Effectiveness and Safety of Durvalumab Alone or Combined with Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment - Mayo Clinic

   Participation eligibility · Patients with vitiligo or alopecia; · Patients with hypothyroidism (e.g., following Hashimoto syndrome), stable on hormone replacement ...

9. A Global, Randomized, Placebo-controlled Phase 3 Study of Fruquintinib in Patients with Refractory Metastatic Colorectal Cancer - Mayo Clinic

   0 grade 1 (except for alopecia or neurotoxicity grade ≤ 2). Known human immunodeficiency virus (HIV) infection. Known history of active viral hepatitis ...

10. Acamprosate (oral route) - Side effects & dosage - Mayo Clinic

    It is not a cure for alcoholism, but rather will help you maintain abstinence. This medicine is available only with your doctor's prescription. This product is ...